NCT00337649View on ClinicalTrials.gov

A Study of Epothilone D in Combination With Herceptin (Trastuzumab) in Patients With HER-2 Positive Advanced or Metastatic Breast Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

May 31, 2004

Primary Completion Date

July 31, 2007

Study Completion Date

July 31, 2007

Conditions
Breast Cancer
Interventions
DRUG

Epothilone D

≤100 mg/m\^2 intravenously (iv) on days 1, 8 and 15 once every 4 weeks

DRUG

Herceptin

4mg/kg iv loading dose, followed by 2mg/kg iv weekly

Trial Locations (6)

28041

Madrid

46009

Valencia

46010

Valencia

08035

Barcelona

08036

Barcelona

08041

Barcelona

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT00337649 - A Study of Epothilone D in Combination With Herceptin (Trastuzumab) in Patients With HER-2 Positive Advanced or Metastatic Breast Cancer | Biotech Hunter | Biotech Hunter